-
METHYLPHENIDATE XR ARX methylphenidate hydrochloride18 mg modified release tablet bottle
Availability: Reduction in supply until supply is exhausted Deletion from market: 30 Jun 2024 -
METHYLPHENIDATE XR ARX methylphenidate hydrochloride 54 mg
Availability: Reduction in supply until supply is exhausted Deletion from market: 31 Jul 2024 -
View Detail
BUPIVADREN Bupivacaine 0.25% w/v with Adrenaline (epinephrine) 1:400,000 injection solution vial
Availability: Reduction in supply until supply is exhausted Deletion from market: 01 Sep 2025 -
View Detail
BUPIVADREN Bupivacaine 0.5% w/v with Adrenaline (epinephrine) 1:200,000 injection solution vial
Availability: Reduction in supply until supply is exhausted Deletion from market: 01 Sep 2025 -
BORTEZOMIB-TEVA bortezomib 3.5 mg
Availability: Reduction in supply until supply is exhausted Deletion from market: 30 Nov 2024 -
ACTEMRA tocilizumab (rch) 162 mg/0.9 mL
Availability: Unavailable Deletion from market: 31 May 2024 -
View Detail
KANJINTI trastuzumab 150 mg
Availability: Reduction in supply until supply is exhausted Deletion from market: 01 Jan 2026 -
SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 25 mg
Availability: Unavailable Deletion from market: 14 Jun 2024 -
SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 50 mg
Availability: Unavailable Deletion from market: 14 Jun 2024 -
SITAGLIPTIN LUPIN sitagliptin (as hydrochloride monohydrate) 100 mg
Availability: Unavailable Deletion from market: 14 Jun 2024 -
View Detail
AZACITIDINE-TEVA azacitidine 100 mg
Availability: Reduction in supply until supply is exhausted Deletion from market: 31 May 2025
